Capricor Therapeutics Inc (NASDAQ:CAPR) shot up 4% during mid-day trading on Friday . The company traded as high as $1.56 and last traded at $1.56. 403,804 shares were traded during trading, a decline of 14% from the average session volume of 467,462 shares. The stock had previously closed at $1.50.
A number of brokerages have issued reports on CAPR. Zacks Investment Research lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 14th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 29th.
The firm has a market cap of $41.57, a price-to-earnings ratio of -3.59 and a beta of -3.29.
Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.63 million. equities analysts expect that Capricor Therapeutics Inc will post -0.42 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in CAPR. Brown Advisory Inc. bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at $1,796,000. Belpointe Asset Management LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $249,000. Jane Street Group LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $190,000. Finally, Wells Fargo & Company MN bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $107,000. Institutional investors and hedge funds own 8.78% of the company’s stock.
WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/15/capricor-therapeutics-capr-shares-up-4.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.